MedTrace Logo

A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002)

NCT01157104 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-01-22

No results posted yet for this study

Summary

This study is designed to evaluate the potential for a pharmacokinetic (PK) drug-drug interaction between IDX320 and IDX184 and to assess the safety and tolerability when the two drugs are administered in combination in healthy participants.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

IDX320

IDX320 400 mg in tablets (8x50 mg) administered orally once daily

DRUG

IDX184

IDX184 100 mg in capsules (2x50 mg) administered orally once daily

DRUG

IDX184 placebo

IDX184 matching placebo in capsules administered orally once daily

DRUG

IDX320 placebo

IDX320 matching placebo in tablets administered orally once daily

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2010-07-31
Completion
2010-08-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01157104 on ClinicalTrials.gov